Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib-Reference-Cited by-同舟云学术

Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib

Published:2019-12-23 Issue:1 Volume:4 Page:
ISSN:2514-1775
Container-title:Rheumatology Advances in Practice
language:en
Short-container-title:

Author:

Yamamura Yuriko¹,Matsumoto Yoshinori¹^ORCID,Asano Yosuke¹,Katayama Yu¹,Hayashi Keigo¹,Ohashi Keiji¹,Morishita Michiko¹,Watanabe Haruki¹^ORCID,Takano-Narazaki Mariko¹,Sada Ken-Ei¹,Wada Jun¹

Affiliation:

1. Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Funder

Okayama University Hospital

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

http://academic.oup.com/rheumap/advance-article-pdf/doi/10.1093/rap/rkz050/31599289/rkz050.pdf

Reference6 articles.

1. Medium- and large-vessel vasculitis;Weyand;N Engl J Med,2003

2. Long-term outcome for 120 Japanese patients with Takayasu's disease. Clinical and statistical analyses of related prognostic factors;Ishikawa;Circulation,1994

3. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690, 550, in rat adjuvant-induced arthritis;Meyer;J Inflamm (Lond),2010